Ovid Therapeutics

Cell and Gene Therapy

TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...

BGN Technologies | November 05, 2020

BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), announced today that it had signed a research collaboration agreement with ECOIBÉRIA in the field of plastic recycling by bacteria, based on research from the team of Prof. Ariel Kushmaro and Prof. Alex Sivan, both from the Laboratory of Environmental Biotechnology and Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at BGU. Polyethylene terephthalate (PET) is the most ab...

Medical

Businesswire | June 07, 2023

Matica Biotechnology, Inc. a contract development and manufacturing organization specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.. Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable. Faster doubling times – Reaching as low as 17 hours, which can significan...

Industrial Impact, Medical

Globenewswire | April 19, 2023

Merck known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling scienc...